Previous 10 | Next 10 |
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today ann...
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, t...
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today an...
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today an...
Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, ...
Genetron Holdings (GTH) and Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical (SBHMY) and a leading liver drug franchise with a major presence in liver disease hospitals in China entered in an exclusive strategic partnership agreement for HCCscreen,...
Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of Sino Biopharm, has a leading liver drug franchise with a major presence in liver disease hospitals in China Genetron Health anticipates that commercialization and revenue growth of HCCscreen ™ will acc...
Four IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. Street research is expected for six companies. Lock-up periods will be expiring for eight companies. For further details see: U.S. IPO Weekly Recap: Airbnb And DoorDash Make Their Public Debuts...
Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed for China approval of at least one of its two COVID-19 inactivated vaccines based on in...
Genetron ([[GTH]] +1.5%) says HCCscreen selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative in China.The goal of the Project is t...
News, Short Squeeze, Breakout and More Instantly...
Genetron Holdings Limited Company Name:
GTH Stock Symbol:
NASDAQ Market:
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and c...
BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and co...